Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Conor J. Gallagher"'
Autor:
Khashayar Dashtipour, Han S. Lee, Aaron Ellenbogen, Rashid Kazerooni, Todd M. Gross, David A. Hollander, Conor J. Gallagher
Publikováno v:
Toxins, Vol 16, Iss 10, p 442 (2024)
The first-line management of cervical dystonia (CD) symptoms is intramuscular injection of botulinum toxin type A (BoNTA). However, a comparison of safety among BoNTAs is difficult because, per regulatory authorities, units of BoNTA activity are not
Externí odkaz:
https://doaj.org/article/e0f2ae7b79d74a43a756af84aeaa7384
Publikováno v:
Plastic and Reconstructive Surgery, Global Open, Vol 12, Iss 3, p e5650 (2024)
Summary:. Good patient outcomes after treatment of the glabellar complex with botulinum toxin type A entail elimination of glabellar lines and maintenance of a natural eyebrow position. A precise injection technique that accurately targets the muscle
Externí odkaz:
https://doaj.org/article/56c8ca52937c497488e6b3a296901d19
Publikováno v:
Toxins, Vol 15, Iss 12, p 683 (2023)
DaxibotulinumtoxinA-lanm for injection (DAXI) is a unique US Food and Drug Administration-approved product comprising daxibotulinumtoxinA and a stabilizing excipient peptide (RTP004). DAXI has a longer-labeled shelf life (72 h) following reconstituti
Externí odkaz:
https://doaj.org/article/54114351522a4339be4201ed04060645
Autor:
Conor J. Gallagher, Ronald R. Bowsher, Amanda Clancy, Jeffrey S. Dover, Shannon Humphrey, Yan Liu, Gregg Prawdzik
Publikováno v:
Toxins, Vol 15, Iss 1, p 60 (2023)
DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A product containing daxibotulinumtoxinA with a stabilizing excipient peptide (RTP004). DAXI immunogenicity was assessed in three phase 3 glabellar line studies (two placebo-con
Externí odkaz:
https://doaj.org/article/e0722c1b95914de6967e1bb40c7a805f
Autor:
Shannon Humphrey, Jeffrey S Dover, Ronald R Bowsher, Amanda Clancy, Yan Liu, Gregg Prawdzik, Conor J Gallagher
Publikováno v:
Aesthetic Surgery Journal.
DaxibotulinumtoxinA-lanm for injection (DAXI), a novel botulinum toxin type A formulation, contains a purified 150-kD core neurotoxin (daxibotulinumtoxinA) and proprietary stabilizing peptide (RTP004), and is approved for glabellar line treatment. As
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c56f2151f11e72eab382e191f62ab95
https://doi.org/10.1093/asj/sjad101
https://doi.org/10.1093/asj/sjad101
Autor:
Joely Kaufman, Nowell Solish, Conor J. Gallagher, Roman G. Rubio, Todd M. Gross, Jean Carruthers
Publikováno v:
Drugs
Botulinum toxin type A (BoNTA) products are widely used for therapeutic and aesthetic indications, but there is a need for longer-lasting treatments that maintain symptom relief between injections and reduce the frequency of re-treatment. Daxibotulin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2544e277bea6f0a24f39094931370c20
http://europepmc.org/articles/PMC8648634
http://europepmc.org/articles/PMC8648634
Autor:
Vince Bertucci, Jeremy B Green, John P Fezza, Jessica Brown, Conor J Gallagher, Nowell Solish
Publikováno v:
Aesthetic surgery journal.
Background Precise injection technique is vital for avoiding suboptimal eyebrow position when treating glabellar lines with botulinum toxin type A. Objectives The aim of this study was to evaluate the impact of glabellar injection technique on eyebro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c10a0d86633cafbf7b0b5f22c55205a
https://pubmed.ncbi.nlm.nih.gov/36583851
https://pubmed.ncbi.nlm.nih.gov/36583851
Publikováno v:
Aesthetic surgery journal.
Background Botulinum toxin type A (BoNTA) injections for the treatment of facial lines may lead to pleasant or undesirable changes in eyebrow height and position. Objectives The aim of this study was to evaluate the impact of glabellar injection of D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fab1bf07e4ba7d11f4d3cac976f1aa7
https://pubmed.ncbi.nlm.nih.gov/36095026
https://pubmed.ncbi.nlm.nih.gov/36095026
Publikováno v:
Dermatologic Surgery
Supplemental Digital Content is Available in the Text.
BACKGROUND DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin in development that has demonstrated efficacy on dynamic glabellar lines. OBJECTIVE To evaluate the effect of r
BACKGROUND DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin in development that has demonstrated efficacy on dynamic glabellar lines. OBJECTIVE To evaluate the effect of r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08e5884618272d2d932638f5ac1db54d
http://europepmc.org/articles/PMC8612903
http://europepmc.org/articles/PMC8612903
Publikováno v:
Aesthetic surgery journal.
Despite the perception that treatment of glabellar lines with botulinum toxin A is straightforward, the reality is that the glabellar region contains a number of interrelated muscles. To avoid adverse outcomes, practitioners need to appreciate how tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::531aa84d5d688c4f7d454a8babd7e2ef
https://pubmed.ncbi.nlm.nih.gov/36322138
https://pubmed.ncbi.nlm.nih.gov/36322138